DR3 antibodies

• US 7,708,996 B2
• Filed: 03/11/2008
• Issued: 05/04/2010
• Est. Priority Date: 03/12/1996
• Status: Expired due to Fees

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Gentz, Reiner L., Yu, Guo-Liang, Ni, Jian, Dillon, Patrick J.
• Primary Examiner(s): Saoud; Christine J
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US12/046,107
• Publication Number:
  US 20080171016A1
• Time in Patent Office: 784 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/4747 Apoptosis related proteins
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C12N 2799/026 where the vector is derived from a baculovirus

Abstract

The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

Claims

1. An isolated antibody or fragment thereof which specifically binds to a polypeptide consisting of amino acids 36 to 212 of SEQ ID NO:

2.

2. The antibody or fragment thereof of claim 1 wherein said polypeptide bound by said antibody or fragment thereof is glycosylated.

3. The antibody or fragment thereof of claim 1 which is a monoclonal antibody.

4. The antibody or fragment thereof of claim 1 which is a polyclonal antibody.

5. The antibody or fragment thereof of claim 1 which is selected from the group consisting of:

(a) a chimeric antibody; and

(b) a humanized antibody.

6. The antibody or fragment thereof of claim 1 which is fused to a heterologous polypeptide.

7. The antibody or fragment thereof of claim 6 wherein said heterologous polypeptide is human serum albumin.

8. An isolated cell that produces the antibody or fragment thereof of claim 1.

9. A hybridoma that produces the antibody or fragment thereof of claim 1.

10. A composition comprising the antibody or fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

11. The antibody or fragment thereof of claim 1 which is selected from the group consisting of:

(a) a Fab fragment;

(b) a Fab′

fragment;

(c) a F(ab′

)2 fragment;

(d) a Fd fragment;

(e) a single-chain Fv (scFv);

(f) a single chain antibody; and

(g) a disulfide-linked Fv (sdFv).

12. The antibody or fragment thereof of claim 11 which is fused to a heterologous polypeptide.

13. The antibody or fragment thereof of claim 12 wherein said heterologous polypeptide is human serum albumin.

14. A composition comprising the antibody or fragment thereof of claim 11 and a pharmaceutically acceptable carrier.

15. The antibody or fragment thereof of claim 11, wherein said antibody or fragment thereof is humanized.

16. The antibody or fragment thereof of claim 15 which is fused to a heterologous polypeptide.

17. The antibody or fragment thereof of claim 16 wherein said heterologous polypeptide is human serum albumin.

18. A composition comprising the antibody or fragment thereof of claim 15 and a pharmaceutically acceptable carrier.

19. A composition comprising the antibody or fragment thereof of claim 17 and a pharmaceutically acceptable carrier.